For the quarter ending 2026-03-31, XFOR had -$365K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -20,241 | -23,925 | -29,815 | -25,459 |
| Gain on sale of non-financial asset | - | 0 | 0 | 0 |
| Stock-based compensation expense | 2,413 | 2,271 | 760 | 1,267 |
| Depreciation and amortization expense | 223 | 223 | 223 | 831 |
| Non-cash lease expense | 374 | 366 | 871 | 1,419 |
| Accretion of debt discount | 230 | 207 | 221 | 437 |
| Change in fair value of warrant liability | -80 | 18 | 676 | -13,472 |
| Other | 106 | 205 | 152 | -196 |
| Accounts receivable | 541 | -318 | -254 | 75 |
| Inventory | 158 | 399 | 910 | 353 |
| Prepaid expenses, other current and non-current assets | -778 | -3,386 | -421 | -441 |
| Accounts payable | -624 | 642 | -2,654 | -967 |
| Accrued expenses and other long-term liabilities | -1,549 | 2,165 | 3,365 | -7,555 |
| Deferred revenue | -59 | -296 | -200 | 1,581 |
| Lease liabilities | -259 | -298 | -882 | -560 |
| Net cash used in operating activities | -19,599 | -15,527 | -27,822 | -42,269 |
| Acquisition of intangible asset | 0 | 0 | 0 | 3,000 |
| Acquisition of property and equipment | - | 0 | 0 | 0 |
| Proceeds from sale of non-financial asset | - | 0 | 0 | 0 |
| Purchase of marketable securities | 0 | 1,901 | 44,534 | 16,953 |
| Sales and maturities of marketable securities | 19,252 | 18,750 | 15,865 | 39,927 |
| Net cash provided by (used in) investing activities | 19,252 | 16,849 | -28,669 | 19,974 |
| Proceeds from exercise of pre-funded warrants | 2 | 52 | 0 | 46 |
| Proceeds from borrowings under loan and security agreement | - | 0 | 0 | 0 |
| Repayments of borrowings under loan and security agreement | - | 0 | - | - |
| Issuance costs for amendments to loan and security agreement and for the sale of warrants accounted as a liability | - | 0 | - | - |
| Proceeds from sale of shares of common stock, warrants and pre-funded warrants, less issuance costs | - | 146,040 | 86,905 | 5,585 |
| Net cash provided by financing activities | 2 | 146,092 | 86,905 | 5,631 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -20 | 3 | -1 | 211 |
| Net decrease in cash, cash equivalents and restricted cash | -365 | 147,417 | 30,413 | -16,453 |
| Cash, cash equivalents and restricted cash at beginning of period | 217,852 | 70,435 | 56,475 | - |
| Cash, cash equivalents and restricted cash at end of period | 217,487 | 217,852 | 70,435 | - |
X4 Pharmaceuticals, Inc (XFOR)
X4 Pharmaceuticals, Inc (XFOR)